Inipharm
Developing Treatments for Severe Liver Disease
- Website
- inipharm.com
- Total Funding
- $35.0M
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 3 investors for this company. The full record is or through the API.
About
Inipharm is a clinical-stage biopharmaceutical company developing therapies for severe liver diseases. Its lead program, INI-822, is a first-in-class small-molecule inhibitor of HSD17B13, a genetically defined target associated with chronic liver disease. Through its Australian subsidiary, the company is conducting a Phase 1 trial that includes patients with MASH while advancing additional small-molecule therapies against the same target.
Summary
Inipharm is a Biotech company. It has raised $35.0M in total across 1 round. Investors include 5AM Ventures, Wu Capital and Frazier Healthcare.
Tech & App Stack
1 technology or app tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/inipharm"><img src="https://indexed.vc/api/badge/company/inipharm" alt="Inipharm on Indexed.vc" width="260" height="76" /></a>